LFWD

Lifeward Ltd. (LFWD) - Q1 2025 10-Q Summary

Business Context and Reporting Period

This report covers the quarterly period ended March 31, 2025. Lifeward Ltd. is a medical device company focused on physical rehabilitation and recovery, offering robotic exoskeletons (ReWalk), anti-gravity systems (AlterG), and soft exo-suits (ReStore). The company operates as a single reportable segment with primary markets in the United States and Europe. As of March 31, 2025, the company had 10,630,281 ordinary shares outstanding.

Key Financial Metrics

Note: The company reported no long-term debt, only operating lease liabilities and other long-term obligations.

Material Changes vs. Prior Period

• Revenue Decline: Revenue decreased 4.7% to $5.03 million, primarily due to the recognition of $0.5 million in rental revenue in Q1 2024 following the establishment of a Medicare reimbursement rate, which did not recur in Q1 2025. This was partially offset by increased AlterG system sales driven by international demand.
• Margin Expansion: Gross margin improved significantly to 42.2% from 26.4%. This was driven by lower production costs following the closure of the Fremont, California facility in late 2024 and the elimination of intangible asset amortization expenses related to the AlterG acquisition.
• Expense Reduction: Operating expenses decreased to $6.98 million from $7.90 million.
  • R&D: Decreased 28.8% to $0.92 million due to the completion of development programs for ReWalk 7 and AlterG NEO.
  • Sales & Marketing: Decreased 23.5% to $3.84 million due to cost savings from AlterG integration and reduced amortization.
  • G&A: Increased 39.5% to $2.22 million, driven by a $0.3 million bad debt expense related to Medicare claims and the absence of a $0.5 million post-closing adjustment benefit recorded in Q1 2024.
• Capital Raise: In January 2025, the company completed a registered direct offering, raising approximately $4.47 million in net proceeds from the sale of 1.82 million shares and warrants.

Outlook, Risks, and Management Commentary

• Going Concern Warning: Management has raised substantial doubt about the company's ability to continue as a going concern. With cash of $5.73 million and a negative operating cash flow of $5.49 million for the quarter, current funds are insufficient to fund planned operations for at least one year. Continued operations depend on securing additional financing.
• Strategic Highlights:
  • Launched the ReWalk 7 personal exoskeleton in the U.S. following FDA clearance.
  • Secured the first commercial health insurance approval for ReWalk 7 reimbursement.
  • Established an exclusive distribution partnership with CorLife (Numotion) for the workers' compensation market.
  • Finalized a reimbursement agreement with BARMER, Germany's second-largest statutory health insurer.
• Risks:
  • Liquidity: Immediate need for capital raises to meet obligations.
  • Trade Policy: New U.S. tariffs on imports from China, Taiwan, and Israel (up to 145%, 10%, and 17% respectively) could increase costs and disrupt the supply chain.
  • Reimbursement: Continued reliance on expanding third-party payer coverage for exoskeletons.
• Subsequent Events: Between March 31 and May 12, 2025, the company sold 374,801 shares under its At-The-Market (ATM) program for net proceeds of approximately $0.5 million.

Investor Verification Checklist

• Cash Runway: Verify the timeline and terms of any upcoming capital raises given the "substantial doubt" disclosure.
• Reimbursement Progress: Monitor the volume of claims approved under the new commercial insurance and BARMER agreements to assess revenue sustainability.
• Supply Chain Impact: Assess the financial impact of new tariffs on manufacturing costs, particularly for components sourced from China and Israel.
• Bad Debt Exposure: Review the resolution of the $0.3 million bad debt expense and potential future write-offs related to Medicare claims.
• ATM Utilization: Track the utilization of the $5.5 million ATM facility established in March 2025.